UK markets close in 2 hours 53 minutes

Almirall, S.A. (0O9B.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
10.34-0.14 (-1.34%)
As of 05:53PM BST. Market open.
Full screen
Previous close10.48
Open10.43
BidN/A x N/A
AskN/A x N/A
Day's range10.36 - 10.57
52-week range10.36 - 10.57
Volume27,577
Avg. volumeN/A
Market cap18.143M
Beta (5Y monthly)0.33
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Investing.com

    Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent

    Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).